IKK is a therapeutic target in KRAS-Induced lung cancer with disrupted p53 activity

Activating mutations in KRAS are prevalent in cancer, but therapies targeted to oncogenic RAS have been ineffective to date. These results argue that targeting downstream effectors of RAS will be an alternative route for blocking RAS-driven oncogenic pathways. We and others have shown that oncogenic...

Descripción completa

Detalles Bibliográficos
Autores principales: Bassères, Daniela S., Ebbs, Aaron, Cogswell, Patricia C., Baldwin, Albert S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2014
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4063255/
https://www.ncbi.nlm.nih.gov/pubmed/24955217

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4063255/
https://www.ncbi.nlm.nih.gov/pubmed/24955217

Ejemplares similares